- Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumoursPublication without faculty affiliation
- An anterior mediastinal mass in a patient with an intestinal neuroendocrine tumour2019 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study2016 | First Faculty of Medicine
- Neuroendocrine tumors of the small bowel2009 | First Faculty of Medicine